ABSTRACT
The Treg/Th17 imbalance is associated with the development of systemic lupus erythematosus (SLE). Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, is isolated from the traditional Chinese herb Artemisia annua Artemisia annua L. This study aims to evaluate the effects of DHA alone or in combination with prednisone in immunodeficiency of SLE. In vivo, the therapeutical effect of DHA alone or in combination with prednisone was assessed in the pristane-induced SLE mouse model. Then, the level of serum antibodies, creatinine (Cre), blood urea nitrogen (BUN), urine protein, kidney histopathology, interleukin (IL)-17, IL-6, transforming growth factor (TGF)-ß, the expression of RORγt and Foxp3, the percentages of Treg and Th17 in peripheral blood and spleen were assayed. In vitro, the mouse spleen lymphocytes were separated and treated with DHA alone or DHA in combination with prednisone. Then the percentages of Treg and Th17, the concentration of IL-17, IL-6, TGF-ß, and the expression of RORγt and Foxp3 were assayed. It was shown that DHA alone or in combination with prednisone treatment significantly alleviated the manifestations of pristane-induced SLE mice, suppressed inflammation and restored the Treg/Th17 balance. DHA alone or in combination with prednisone significantly inhibited Th17 cell differentiation while induced Treg cell differentiation in vitro. DHA alone or in combination with prednisone also reduced the transcription of RORγt and increased Foxp3 in lymphocytes, as well as IL-17 and TGF-ß levels. Our data indicated that DHA can produce synergistic effect with prednisone to attenuate the symptoms of SLE by restoring Treg/Th17 balance.
Subject(s)
Lupus Erythematosus, Systemic , Animals , Artemisinins , Cell Differentiation , Mice , Prednisone , Th17 Cells , Transforming Growth Factor betaABSTRACT
OBJECTIVE: To evaluate the anti-fibrotic effects of Astragaloside IV in systemic sclerosis. METHODS: Treated or untreated systemic sclerosis (SSc) and normal fibroblast isolated from corresponding pairs were utilized to detect expression of collagen and fibronectin by western blot, quantitative real-time RT-PCR (RT-qPCR), immunofluorescence staining and histopathological examination. SSc mouse model induced by bleomycin was used to evaluate the effects of the drug in vivo. RESULTS: Compared to normal fibroblast (NF), the expression of collagen and fibronectin in SSc (SScF) dramatically increased, and this could be reduced by Astragaloside IV (AST) in a dose- or time-dependent manner at both protein and mRNA levels. Administration of Astragaloside IV consistently decreased collagen formation and partially restored the structure, as well as suppressing collagen and fibronectin expression in the skin lesions of SSc-model mice. Mechanistically, Astragaloside IV-induced fibrosis reduction may be due to deregulation of Smad 3/Fli-1, the major mediators of the fibrotic response and key molecules for TGF-ß signaling. Astragaloside IV also decreased the level of p-SMAD3 and completely blocked its relocation into the nuclei. CONCLUSION: Astragaloside IV attenuates fibrosis by inhibiting the TGF-ß-Smads3 axis in systemic sclerosis.
Subject(s)
Saponins/administration & dosage , Scleroderma, Systemic/drug therapy , Scleroderma, Systemic/genetics , Smad3 Protein/biosynthesis , Transforming Growth Factor beta/biosynthesis , Triterpenes/administration & dosage , Animals , Disease Models, Animal , Fibroblasts , Fibrosis/drug therapy , Fibrosis/genetics , Fibrosis/pathology , Humans , Mice , RNA, Messenger , Scleroderma, Systemic/pathologyABSTRACT
Although miR-5195-3p has been acknowledged for its tumor suppressor role in diverse cancer categories, its precise functions and mechanisms concerning melanoma have not been comprehensively elucidated. In this study, we employed quantitative reverse transcription PCR, Western blot analysis, and immunohistochemistry staining to investigate the expression patterns of miR-5195-3p and poly (rC) binding protein 2 (PCBP2) in melanoma tissues compared to adjacent tissues. Our findings revealed downregulation of miR-5195-3p and upregulation of PCBP2 in melanoma tissues. Through the implementation of a luciferase reporter assay, we successfully identified PCBP2 as a newly discovered target of miR-5195-3p in melanoma cells. Enforced expression of miR-5195-3p via mimics inhibited cell proliferation and migration in A375 and A2058 cells, as demonstrated by CCK-8 and transwell migration assays. In melanoma cells, reintroduction of PCBP2 partially reversed the inhibitory effects of miR-5195-3p overexpression. Treatment with LY294002, an inhibitor of the PI3K/AKT signaling pathway, also reversed the effects of PCBP2 in melanoma cells. Furthermore, our results suggest that miR-5195-3p inhibits the activation of the PI3K/AKT signaling pathway in melanoma by inhibiting PCBP2. In conclusion, our research has identified the miR-5195-3p targeting of the PCBP2-mediated PI3K/AKT signaling pathway as a potential therapeutic target for melanoma treatment.
ABSTRACT
This study aimed to investigate whether shikonin combined with methotrexate could inhibit psoriasis progression by regulating the polarization of macrophages through in vivo and in vitro experiments. Imiquimod was administrated to the exposed skin of BALB/c mice, and shikonin and methotrexate suspension were also given by gavage. The erythema, scales and thickness were scored for mice lesions in each group, and the total score was obtained by adding the above three scores, and calculated as psoriasis area and severity index (PASI) score. The skin lesion tissue from mice was isolated and used for hematoxylin-eosin staining and immunohistochemistry assay. Drug-containing serum was prepared and administrated into mouse macrophage RAW264.7 cells, followed by simulation of LPS. The levels of tumor necrosis factor-α (TNF-α), Interleukin (IL)-1ß, and IL-6 in cell supernatant were assessed using ELISA Kits and real-time PCR. In imiquimod-induced psoriasis mice, shikonin combined with methotrexate exerted protective effects by reducing erythema and PASI scores, decreasing backer score and epidermal thickness, and particularly regulating macrophage polarization. In LPS-stimulated RAW264.7 cells, shikonin combined with methotrexate regulated M1/M2 polarization and altered the levels of M1 markers. Shikonin combined with methotrexate inhibit psoriasis progression by regulating the polarization of macrophages, which may be useful in the treatment of psoriasis.
Subject(s)
Methotrexate , Psoriasis , Animals , Imiquimod/adverse effects , Lipopolysaccharides , Macrophages/pathology , Methotrexate/adverse effects , Mice , Naphthoquinones , Psoriasis/drug therapyABSTRACT
BACKGROUND: The efficacy and safety of integrated Chinese and western medicine in the treatment of Systemic Lupus Erythematosus (SLE) have not been systematically evaluated. METHODS: This systematic review and meta-analysis will be performed and reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We will search PubMed, Embase, Cochrane Library, Chinese Biomedical Database WangFang, VIP, and China National Knowledge Infrastructure (CNKI) for potentially eligible studies from their inception to Dec. 2020, and we will select all the eligible randomized controlled trials (RCTs) of the integrated Chinese and western medicine for Systemic Lupus Erythematosus. All the studies will be screened according to the inclusion and exclusion criteria and meta-analysis will be conducted using Review Manager V.5.3. and Stata V.12.0. The primary endpoint was the clinical efficacy rate, the secondary outcomes were SLEDAI score, adverse reaction rate, and laboratory test parameters (white blood cells, complement C3). RESULTS: The results of this study will systematically evaluate the effectiveness and safety of the integrated Chinese and western medicine in the treatment of primary dysmenorrhea. CONCLUSION: The efficacy and safety of integrated Chinese and western medicine will be systematically evaluated in this paper, thus providing evidence for the clinical application of this therapy. ETHICS AND DISSEMINATION: This study is a systematic review, which is based on the published studies, so examination and agreement by the ethics committee are not required in this study. We intend to publish the study results in a journal or conference presentations. OPEN SCIENCE FRAMEWORK OSFREGISTRATION NUMBER: https://osf.io/mabxh.
Subject(s)
Drugs, Chinese Herbal/therapeutic use , Glucocorticoids/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Drug Therapy, Combination/methods , Humans , Lupus Erythematosus, Systemic/diagnosis , Meta-Analysis as Topic , Randomized Controlled Trials as Topic , Severity of Illness Index , Systematic Reviews as Topic , Treatment OutcomeABSTRACT
Psoriasis is an immunemediated dermatosis characterized by Tlymphocytemediated epidermal hyperplasia, for which there are currently no effective clinical treatments. 'Psoriasis 1' is a Chinese herbal medicine formulation that has been recently used extensively in China for treating patients with psoriasis. However, the molecular mechanism of action of this potent formulation has not yet been fully elucidated. In the present study, the effects of 'Psoriasis 1' on T ymphocytes in patients with psoriasis were investigated and the underlying molecular mechanism was discussed. Blood samples were collected from 40 patients with psoriasis. ELISA was employed to assess the levels of tumour necrosis factorα, interferonγ, interleukin (IL)2, IL6, transforming growth factorß, IL4, IL12, IL23 and vitamin D (VD). Western blot and quantitative PCR analyses were used to investigate the expression levels of VD receptor (VDR) and signal transducer and activator of transcription (STAT)4 in T lymphocytes. 'Psoriasis 1' was observed to significantly increase CD4+ T cells. It also notably upregulated the mRNA and protein expression of VDR, and downregulated the mRNA and protein expression of STAT4. Moreover, the suppression of VDR was found to aggravate the inflammatory response, which was reversed by 'Psoriasis 1.' Thus, this formulation reportedly decreased the inflammation mediated by T lymphocytes in patients with psoriasis through inhibiting VDRmediated STAT4 inactivation.
Subject(s)
CD4-Positive T-Lymphocytes/metabolism , Inflammation/metabolism , Psoriasis/metabolism , Receptors, Calcitriol/metabolism , STAT4 Transcription Factor/metabolism , Vitamin D/metabolism , Adult , Cytokines/metabolism , Female , Humans , Keratinocytes/metabolism , Male , Middle Aged , RNA, Messenger/metabolism , Signal Transduction/physiology , Skin/metabolism , Young AdultABSTRACT
'Psoriasis 1', a Chinese herbal medicine (CHM) formulation, is extensively used to treat psoriasis in China. Although this CHM formulation yields good therapeutic effect, the underlying mechanism of how this works remains unknown. The present study aimed to test the hypothesis that the CHM formulation 'psoriasis 1' inhibits vitamin D receptor (VDR)mediated inflammation in psoriasis. To test this, a model of psoriasis was established by stimulating keratinocytes (HaCaT cells) with tumor necrosis factor (TNF)α; these cells were subsequently transfected with a lentiviral VDR RNA interference expression vector. The expression levels of 25hydroxyvitamin D3 (25HVD3), TNFα, interleukin (IL)4, IL1, IL17C, IL23 and IL6 were measured using ELISA, and the expression levels of VDR, inhibitor of nuclear factor (NF)κB (IKK), NFκB, signal transducer and activator of transcription (STAT) 3 and STAT4 were measured using reverse transcriptionquantitative polymerase chain reaction analysis and western blotting. It was observed that 'psoriasis 1' downregulated the concentrations of TNFα, IFNγ, IL22, IL17C, IL1ß and IL4, and upregulated the concentration of 25HVD3; furthermore, 'psoriasis 1' downregulated the expression levels of NFκB, phosphorylated (p)NFκB, IKK, pIKK, STAT3, pSTAT3, STAT4 and pSTAT4, and upregulated the expression level of VDR in TNFαinduced HaCaT cells. These results suggested that 'psoriasis 1' suppressed the inflammatory response and the activation of the NFκB and STAT signaling pathways. In addition, it was identified that silencing VDR expression decreased the levels of TNFα, IFNγ, IL22, IL17C, IL1ß and IL4, and increased the level of 25HVD3; silencing VDR expression additionally downregulated the expression levels of NFкB, pNFкB, IKK, pIKK, STAT3, pSTAT3, STAT4 and pSTAT4, and upregulated the level of VDR in TNFαinduced HaCaT cells. It was concluded that 'psoriasis 1' exerts inflammationsuppressive effects in psoriasis by suppressing the NFкB and STAT signaling pathways.
Subject(s)
Drugs, Chinese Herbal/therapeutic use , NF-kappa B/metabolism , Psoriasis/drug therapy , Receptors, Calcitriol/metabolism , STAT3 Transcription Factor/metabolism , STAT4 Transcription Factor/metabolism , Animals , Cytokines/analysis , Cytokines/genetics , Cytokines/metabolism , Down-Regulation/drug effects , Drugs, Chinese Herbal/pharmacology , Humans , Inflammation/pathology , Inflammation/prevention & control , Male , NF-kappa B/genetics , Phosphorylation/drug effects , Psoriasis/metabolism , Psoriasis/pathology , RNA Interference , RNA, Small Interfering/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Calcitriol/antagonists & inhibitors , Receptors, Calcitriol/genetics , STAT3 Transcription Factor/genetics , STAT4 Transcription Factor/genetics , Signal Transduction/drug effects , Tumor Necrosis Factor-alpha/pharmacology , Up-Regulation/drug effectsABSTRACT
AIM: Geniposide is an iridoid glycoside isolated from the gardenia plant. It has multiple biological activities. The roles of geniposide in systemic sclerosis (SSc) and in endothelial-to-mesenchymal transition (EndMT) are unclear. We investigated the protective effects of geniposide in a bleomycin-induced SSc mouse model, and its potential mechanisms. METHODS: The effects of geniposide were evaluated as follows: (1) histological and immunochemical changes in mouse skin tissue; (2) changes in cellular morphology of human umbilical vein endothelial cells (HUVECs); (3) expression of endothelial cell biomarkers (E-Cadherin, CD31, and CD34), mesenchymal cell markers (FSP1, Collagen, and α-SMA), and key factors of EndMT (Slug, Snail, and Twist) using real time PCR, Western blot, and immunofluorescence; (4) tube formation in HUVECs; (5) mTOR signaling pathway transcription factors using Western blot analysis. RESULTS: Treatment with bleomycin induced up-regulation of mesenchymal cell biomarkers and down-regulation of endothelial cell biomarkers in in vivo and in vitro bleomycin-induced scleroderma models. Geniposide treatment suppressed these effects. Geniposide remedied bleomycin-induced dermal capillary loss and fibrosis in mice. The expression of key EndMT factors (Slug, Snail, and Twist) and the mTOR signaling pathway (mTOR and S6) were also attenuated by geniposide treatment. CONCLUSION: Geniposide had protective effects on endothelial cells in the bleomycin-induced scleroderma mouse model. These effects may occur via inhibition of the mTOR signaling pathway activation. The results suggested that geniposide could be a potential candidate drug for treatment of vascular damage in SSc patients.